ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 08, 2019 19:00 JST
Source:
Holista CollTech Ltd
iGalen and Holista announce resolution with ATM Metabolics
PERTH, W AUSTRALIA, Nov 08, 2019 - (ACN Newswire) - Holista, a research-driven biotech company that develops natural ingredient and wellness products, and its distributor iGalen are pleased to announce that they have resolved their disputes with ATM Metabolics and its founder Dr. Joseph Ahrens, a two time Nobel prize nominee and discoverer of Emulin. As a result, they will no longer be carrying Emulin.
If you would like to purchase the product in the future, please contact ATM at www.atmmetabolics.com. We wish ATM and Dr. Ahrens success in their future endeavours, and thank them for working with us to resolve the disputes.
Holista CollTech (ASX:HCT) is a research-driven biotech company. Headquartered in Perth with operations in Malaysia, it is dedicated to delivering first-class natural ingredients and wellness products globally. Holista's ingredients include low-GI baked products, reduced-sodium salts, low-fat fried foods and low calorie sugar. www.holistaco.com.
iGalen markets a range of premium-quality nutritional supplements that are sold directly to Distributors and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Singapore, Mexico, Malaysia, and the Philippines. Visit www.igalen.com.
Source: Holista CollTech Ltd
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Hitachi High-Tech Launches DCR Etch System 9060 Series, Supporting Isotropic Etching of Advanced 3D Devices at the Atomic Level
Nov 28, 2024 11:31 JST
MHI Delivers Final Trainset of Automated Guideway Transit System "2020 Series" to Saitama New Urban Transit
Nov 28, 2024 10:08 JST
TOPVISION Launches Prospectus for Listing Transfer from LEAP to the ACE Market
Nov 27, 2024 05:53 JST
TOYOTA GAZOO Racing FULLY PREPARED FOR DAKAR 2025
Nov 26, 2024 17:55 JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 26, 2024 15:50 JST
Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST
TOYOTA GAZOO Racing reinforces WRC line-up with youth and experience for 2025
Nov 25, 2024 17:10 JST
Toyota Submits Progress Report on Recurrence Prevention Measures
Nov 25, 2024 15:43 JST
TOPVISION Launches Prospectus for Transfer Listing from LEAP to the ACE Market
Nov 25, 2024 15:00 JST
MHI Thermal Systems Receives Order from Aisan Industry for Aquifer Thermal Energy Storage System for Its New Anjo Plant
Nov 25, 2024 14:18 JST
Oracle Red Bull Racing Driver Max Verstappen Wins Fourth Consecutive F1 Drivers' World Championship
Nov 25, 2024 11:55 JST
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
More Latest Release >>
Related Release
Berjaya Partners Holista to Offer Healthy Breads and Foods in Starbucks Malaysia, 7-Eleven and Other F&B Outlets
October 12 2021 17:00 JST
Malaysia Permission Granted for COVID-19 Test Kit from China for Emergency Use; Homegrown Holista Colltech Receives Initial Order for 15,000 Units for Deployment
June 18 2021 14:00 JST
US Tests Confirm Path-Away(R) Organically Kills SARS-CoV-2 Virus
October 21 2020 21:00 JST
Holista Signs Agreement with Costanzo's to Launch World's Lowest Glycaemic Index (GI) Clean Label Bread
October 01 2020 15:00 JST
Path-Away(R), Active Ingredient in Plant-Based, Alcohol-Free NatShield(TM) Hand Sanitiser by Holista CollTech, Tested >99.99% Effective against COVID-19 Surrogate
April 21 2020 06:30 JST
Skin Elements Enters Binding Agreement with Holista Colltech To Launch All Natural Skin-Friendly Sanitiser
April 03 2020 17:00 JST
Holista Partners GICC LLC, the U.S. Developer of Path-Away(R), to Co-Develop Nasal Sanitising Balm for Global Markets
February 20 2020 16:00 JST
Malaysians Rush for Anti-Virus Sanitiser, NatShield(TM), after Pharmacies Restock on Concerns of Spread of Deadly Disease
February 06 2020 16:00 JST
Orders for NatShield Sanitizer Spike after Outbreak of Coronavirus
January 30 2020 16:00 JST
Holista Files Patent for Water-Soluble Technology Targeting Cannabidiol (CBD) and Fat-Soluble Nutraceuticals
December 13 2019 13:00 JST
More Press release >>